Pfizer started its Phase 1 clinical trial for its anti-COVID-19 capsule.
American drugmaker Pfizer had already started the Phase 1 clinical trial for its anti-COVID-19 capsule in the United States.
Pfizer had started the Phase 1 clinical trial for its capsule that would be a possible cure for COVID-19.
In a report on GMA News’ 24 Oras, the Phase 1 clinical trial for Pfizer’s anti-COVID-19 capsule — called “PF-07321332” — will be conducted on healthy adults in the United States.
As per the report, the said capsule was a “protease inhibitor” which bound to a viral enzyme and prevented SARS-CoV-2 (COVID-19 causative agent) from replicating in the cell. Protease inhibitors were also effective in treating other diseases such as hepatitis C virus and HIV.
Also, Pfizer’s anti-COVID-19 oral capsule will be a potential therapy that would be given to COVID-19 patients without critical care or hospitalization.
Pfizer CEO Albert Bourla said in an interview with CNBC that the drug may be available in the United States before 2021 ends if clinical trials showed that the capsule was effective for preventing COVID-19.
Meanwhile, Health Undersecretary Maria Rosario Vergeire said that they’ll be looking into the study as the Philippines will get access to the capsule once Pfizer completed its clinical trials and found that the said drug was effective.